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Abstract
Avian species are highly susceptible to the hepatotoxic mycotoxin aflatoxin B1 (AFB1).
Domesticated turkeys are exquisitely sensitive, due to a combination of highly-efficient hepatic
cytochrome P450 (CYP)-mediated bioactivation, and to dysfunctional alpha-class glutathione Stransferases (GSTAs) which typically detoxify the bioactivated electrophilic metabolite exoAFB1-8,9-epoxide (AFBO). Wild turkeys are relatively resistant to AFB1 in large part due to
expression of functional GSTAs. Quail, a related Galliforme, are slightly less sensitive in vivo to
AFB1, but whether this is related to the hepatic metabolic profiles of these two critical enzymes
has not been rigorously evaluated. The purpose of this study was to compare hepatic CYPmediated bioactivation and GST-mediated detoxification activities toward AFB1 in Callipepla
californica (HQ) and Coturnix japonica (JQ) against those from domesticated Broad-breasted
White (BB) or Eastern Wild (EW) turkeys. Although Callipepla californica is commonly known as
the California quail, the flock investigated in this study originated in Hawaii, hence use of the
identifier “HQ” (noted above) that will be used throughout this report. Hepatic expression of
CYP1A5 was significantly greater in both quail species, whereas there was no difference in
CYP3A37 expression between species. Likewise, livers from both quail species expressed
significantly greater GSTA3 than that from both turkey types, whereas turkeys expressed
greater hepatic GSTA4 than those from both quail species. Kinetic analysis confirmed that liver
microsomes from turkeys bioactivated AFB 1 more efficiently (high Vmax, Kcat; low Km) than those
from quail, whereas hepatic cytosols from quail were significantly more efficient in detoxifying
AFBO than those from turkeys. Conversely, turkey hepatic cytosols were more efficient than
quail at detoxifying GST indicator substrates 1-chloro-2,4-dinitrobenzene (CDNB), ethacrynic
2

acid (ECA), and cumene hydroperoxide (CHP), but not 1,2-dichloro-4-nitrobenzene (DCNB),
indicating greater presence of GST isoforms not relevant to AFB 1 detoxification. In total, our
data shows that the relative resistance of quail compared to turkeys is reflected in the relatively
lower in vitro bioactivation and higher detoxification activities.
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Aflatoxins: Overview
Aflatoxins are one of the most important mycotoxins in terms of occurrence and
potency (Pitt, 2013). Aflatoxin B1 (AFB1; Figure 1) was discovered when it was identified as the
etiological agent of “Turkey X Disease” in 1960, which caused extensive and widespread deaths
of turkeys and other poultry species across Europe. The source of AFB1 that caused the disease
outbreak was traced to contaminated Brazilian peanut meal a widely used feed ingredient for
poultry (Blount, 1961; Stevens et al., 1960). This event demonstrated the extreme sensitivity of
turkeys to this mycotoxin, and it is now clear that domesticated turkeys (Meleagris gallopavo)
are one of the most sensitive animals known (Kim et al., 2013; Monson et al., 2015).
Aflatoxins are naturally occurring
metabolites produced by the fungus
Aspergillus flavus, A. parasiticus, and others.
Derivatives of difuranocoumarin, individual
aflatoxins (AFs) are named according to their
blue (B) or green (G) fluorescence under UV

Figure 1: Chemical structure of Aflatoxin B1

light and elution position on a thin-layer
chromatograph, hence AFB1, AFB2, AFG 1, and
AFG2 (Dalvi, 1986; Yu et al., 2004); of these, AFB1 is the most potently hepatotoxic, mutagenic,
and carcinogenic (Coulombe, 1993; Monson, et al., 2015; Rawal, et al., 2010a). Aflatoxin B1 is
hepatocarcinogenic in livestock, laboratory animals, and humans (Kim, et al., 2013; Wogan,
1992). Aflatoxin B1 is also considered a "pro-carcinogen", because it requires enzymatic
bioactivation for its carcinogenic and toxic effects to occur (Diaz et al., 2010a; Diaz et al., 2010b;
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Rawal and Coulombe, 2011; Rawal, et al., 2010a). Aflatoxin B 1 also acts as a "force multiplier"
synergizing the adverse effects of microbial and viral pathogens, and other agents (Monson, et
al., 2015). While AFB1 is toxic to every animal species examined, the primary focus of this
review is on the effects of this mycotoxin in poultry, specifically turkey and quail. When
relevant, molecular mechanisms of toxicity in other species that may also aid in our
understanding of a response in poultry will be briefly presented.

Aflatoxins: Toxicity and Carcinogenicity
The acute and chronic diseases caused by AFB1 consumption are termed aflatoxicoses
(Bennett and Klich, 2003). Aflatoxin B1 affects the liver as the primary target organ, where it
causes hemorrhagic necrosis, fatty infiltration, and bile duct proliferation (Coulombe, 1993).
Chronic AFB1 exposure results in immunosuppression, as well as reductions in growth rates,
productivity, fertility, feed utilization, milk production, and egg production (Diekman and
Green, 1992; Galvano et al., 1996; Monson, et al., 2015; Pandey and Chauhan, 2007;
Polychronaki et al., 2006).
Species susceptibility to the acute toxic effects of AFB1 varies considerably. Mice are one
of the most resistant species to both the acute and chronic toxic effects of AFB1 whereas rats,
fish, and poultry are extremely sensitive to both (Bailey et al., 1988; Bedard et al., 2005; Gold et
al., 1984; Klein et al., 2002a; Monson, et al., 2015; Rawal, et al., 2010a; Wogan, 1992). Chronic
aflatoxicosis inflicts an estimated US$143 million yearly loss to the turkey industry in the United
States from hepatotoxicity, reduced performance, and secondary infections (CAST, 1989, 2003).
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Acute AFB1 exposure leads to structural and functional damage to the liver (Busby and
Wogan, 1984). The clinical signs and pathological changes associated with acute AFB1 exposure
in humans include vomiting, abdominal pain, pulmonary edema, and fatty acid infiltration into
the liver (Shank et al., 1972); and in animals there are parenchymal cell necrosis, bile duct
proliferation, and hepatic lesions (Newberne and Butler, 1969). Additionally, acute toxicosis
may be associated with an increased future risk of cancer, through the formation of DNA
adducts, especially in transcriptionally active genes (Irvin and Wogan, 1984; Yu, 1983). Acute
toxicosis in turkeys is evident by enlarged mottled livers that have periportal necrosis,
hemorrhage, and accumulation of fat (Wannop, 1960).
Chronic exposure more readily leads to cancer than does acute exposure (Edds, 1973).
In rats chronic treatment of AFB 1 resulted in failure to gain body weight, loss of liver weight,
and loss of hepatic DNA content (Liu et al., 1988). The clinical signs of chronic AFB1 exposure are
anemia; jaundice; anorexia; hemorrhage; embryotoxicity; increased susceptibility to
environmental and microbial stressors; hepatic necrosis; hepatobiliary hyperplasia; and it can
alter the gut microbiota allowing colonization of gut pathogens (CAST, 2003; Klein et al., 2002b;
Reed et al., 2019).

Aflatoxin B1: Metabolism
Once ingested, AFB1 is initially converted by oxidative phase I hepatic enzymes to a
number of metabolites, many of which are detoxified and excreted per se, whereas others are
of greater bioactivity. Many phase I metabolites are further metabolized through one or more
secondary (phase II) conjugations with endogenous endocons such as glucuronic acid and
9

glutathione (GSH) (Deng et al., 2018; Lozano and Diaz, 2006). Aflatoxin B1 requires prior
bioactivation by cytochrome P450s to become toxic, as shown in Figure 2 (Ball and Coulombe,
1991; Coulombe, 1993). The main bioactive metabolite is the electrophilic and highly reactive
exo-AFB 1-8,9-epoxide (AFBO), which reacts with cellular macromolecules, most significantly
DNA to form the AFB1- N7-guanine adduct that is the principal mutagenic and carcinogenic
cellular lesion (Ball et al., 1990; Iyer et al., 1994). Although AFBO is the most toxic, other
metabolites of AFB1 include aflatoxin M1 (AFM1; first named due to its prevalence in cow's
milk), aflatoxin Q1 (AFQ1), and aflatoxicol (AFL) (Coulombe, 1993; Monson, et al., 2015) (Figure
2).
Aflatoxin M1 (4-hydroxy AFB1; AFM1) represents the primary hydroxylated metabolite of
AFB1. Aflatoxin M1 is classified as a group 2B carcinogen, possibly carcinogenic to humans. In
the United States, the maximum acceptable limit of AFM1 in fluid milk products is 0.5 ppb.
Aflatoxin Q1 is the 3-hydroxy metabolite of AFB1 and is considerably less toxic than AFB1 (IARC,
2012; Raney et al., 1992).
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Figure 2: The extreme sensitivity of turkeys to AFB1 is associated with efficient AFB1 epoxidation catalyzed by CYP1A5 and
CYP3A37, coupled with deficient GST detoxification. The hydroxylated metabolites, AFM1, and AFQ1 are formed by CYP1A5 and
CYP3A37, respectively. Dashed line indicates this critical detoxification pathway is deficient in domesticated turkeys. Adapted
from (Rawal et al., 2010a).

Role of Cytochrome P450 in AFB1 Metabolism
The principal phase I metabolic enzymes that metabolize AFB1 are the cytochrome P450
proteins (CYPs), hemeproteins principally located in the smooth endoplasmic reticulum (Nebert
and Russell, 2002). An important endogenous role of CYPs is to catalyze the synthesis of steroid
hormones (hCYP17A1, 19A1, 21A2), cholesterol (hCYP11A1, 27A1, 39A1) and bile acids
(hCYP7A1, 27A1) (Guengerich, 2017; Nebert and Russell, 2002; Staels and Fonseca, 2009).
Cytochrome P450s are named and classified according to nucleotide and amino acid sequence
homology by a family number (e.g., CYP1, CYP3) and a subfamily letter (e.g., CYP1A, CYP3A)
11

then by isoform number (e.g., CYP1A5, CYP3A37) (McDonnell and Dang, 2013). Additionally, a
lowercase letter can precede the cytochrome designation to indicate species of the enzyme, for
example, mouse (mCYP1A2) or turkey (tCYP1A5).
In turkeys, AFB1 is metabolized primarily by two hepatic P450s, CYP1A5 and CYP3A37
(Rawal and Coulombe, 2011). For example, AFQ1 is the principal product of tCYP3A37
metabolism, and AFM1 is produced primarily by tCYP1A5 (Rawal and Coulombe, 2011). Both
isoforms bioactivate AFB 1 to AFBO, but show significant substrate affinities in that tCYP1A5
predominates at low, pharmacologically-relevant concentrations (~0.1 μM), whereas CYP3A37
catalysis is significant only at much greater (> 50 µM) concentrations of AFB1 that are unlikely to
be achieved in vivo in most if not all “real world” exposures (Rawal and Coulombe, 2011).
The relative contribution of both microsomal CYP1A5 and CYP3A37 AFB1 bioactivation is
approximately 98% and 2%, respectively, at sub-micromolar (0.1 µM) concentrations of AFB1
(Rawal and Coulombe, 2011). At 0.1 µM AFB1, CYP1A5 produces a higher ratio (50:1) of
bioactivation to detoxification product (AFBO:AFM1) compared to CYP3A37 (AFBO:AFQ1 =
0.17:1) (Rawal and Coulombe, 2011). Using custom anti-peptide antibodies to perform a series
of immunoinhibition experiments to independently characterize CYP 1A5 and 3A37 metabolism
in hepatic microsomes, two kinetic models were observed (Rawal and Coulombe, 2011; Yip and
Coulombe, 2006). At sub-micromolar AFB1 concentrations CYP1A5 is characterized by
hyperbolic Michaelis kinetics producing only AFBO and AFM1 (Rawal and Coulombe, 2011).
Identical kinetics have been observed from E. coli that expressed tCYP1A5 (Yip and Coulombe,
2006) and hCYP1A2 (Gallagher et al., 1996). The inhibitory effect of BHT on CYP1A5 exhibited
Michaelis competitive inhibitory kinetics (Ki = 0.81 µM) (Guarisco et al., 2008). Conversely,
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when CYP1A5 was immunoinhibited, isolating CYP3A37 catalysis, turkey liver microsomes
produced AFBO and AFQ1, following sigmoidal Hill kinetics (Rawal and Coulombe, 2011). The
sigmoidal relationship observed between the substrate concentrations and the rates of product
formation suggests cooperativity between CYP3A37 and AFB1 (Rawal and Coulombe, 2011). This
relationship was explored previously in our laboratory where E. coli expressed CYP3A37
exhibited a sigmoidal relationship suggesting that both AFBO and AFQ1 formation is driven by
an allosteric interaction between AFB1 and CYP3A37, showing positive cooperativity (Rawal et
al., 2010b).
The epoxidation of AFB1 to form AFBO is the most critical step in the toxic and
carcinogenic effects of this mycotoxin (Rawal, et al., 2010b). Turkey hepatic P450s are among
the most efficient at bioactivating AFB 1 to AFBO compared to other poultry species, specifically
ducks, quail, chickens, and pheasants (Monson, et al., 2015; Rawal and Coulombe, 2011).
Cytochrome P450s of turkey poults are more active toward AFB1 than those of mature birds
(Klein, et al., 2002a). The dominant catalyst of AFB1 epoxidation at low, environmentallyrelevant concentrations found in poultry liver is CYP1A5 (Rawal and Coulombe, 2011). The
critical role of CYP1A5 was further illustrated by the use of butylated hydroxytoluene (BHT) an
hCYP1A5 inhibitor to alleviate the symptoms of aflatoxicosis in AFB1 exposed poultry (Guarisco,
et al., 2008).

Aflatoxin B1: Carcinogenicity
Aflatoxin B1 is one of the most potent hepatocarcinogens known, and its potency has
been established in numerous avian, mammalian, aquatic, and non-human primate species
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(Bailey et al., 1984; Eaton and Schaupp, 2014; Monson, et al., 2015; Muller et al., 1970).
Numerous epidemiological and clinical studies have led the International Agency for Research
on Cancer (IARC) to classify AFB1 as a class 1 or recognized human carcinogen (IARC, 1993).
Essential to AFB 1 toxicity and carcinogenesis is the formation of the N7-guanine adduct (Figure
3), the principal mutagenic and carcinogenic cellular lesion in animals (Ball, et al., 1990; Iyer, et
al., 1994). Bailey et al. (1988) demonstrated that rainbow trout, when exposed to AFB1,
exhibited an 62% tumor incidence after 12 months compared to Coho salmon that had no
incidence of tumors when they were treated identically. Additionally, that study demonstrated
that rainbow trout AFB-DNA binding is 18 times greater than salmon AFB-DNA binding after a
three-week dietary exposure to AFB1 (Bailey, et al., 1988). Studies working with rats have
shown that through the use of a detoxifying enzyme inducer, Oltipaz, N7-guanine adducts could
be reduced by 97% with no incidence of AFB1-induced hepatocellular neoplasms (Kensler et al.,
1985; Roebuck et al., 1991). The AFBO metabolite has also been found to cause genetic damage
in bacteria, as well as in human and animal cells (IARC, 2012). Cancer results from the
introduction of a G→T transversion in hepatic DNA in human hepatocytes (Mace et al., 1997);
this is the result of AFB1 adducts predisposing DNA synthesis machinery to make G→T
transversions (Smela et al., 2002). The G→T transversion is the predominant mutation induced
by AFB1 exposure (Foster et al., 1983). The specific mutation is made to codon 249 of the p53
tumor suppressor gene (IARC, 2012; Kensler et al., 2011; Mace, et al., 1997), which occurs in
more than half of the patients with hepatocellular carcinoma (HCC)(Bressac et al., 1991; Hsu et
al., 1991).
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Figure 3: Metabolites and enzymes involved in aflatoxin B1 (AFB1) metabolism in turkey liver microsomes. Hepatic glutathione Stransferases (GSTs) from domesticated turkeys lack exo-AFB1-8,9-epoxide (AFBO) conjugating activity (dashed line), while those from
wild turkeys are fully functional. [Adapted from Monson, et. al., 2015]

Role of Glutathione S-transferases in AFB1 Detoxication
Phase II metabolism is an enzymatic process whereby a phase I metabolite is conjugated
with an endogenous cofactor, or “endocon” such as glucuronic acid, sulfate acetic acid, or
glutathione with the resultant metabolite being safely excreted(Zamek-Gliszczynski et al., 2006)
. In nearly all animals studied, the primary route of AFB 1 detoxification is through hepatic
glutathione S-transferases (GSTs) which are critical phase II detoxification enzymes that
specifically recognize, react with, and detoxify electrophilic intermediates, such as AFBO, by
conjugating this reactive intermediate with the cofactor glutathione (GSH)(Coles and Kadlubar,
15

2003). Glutathione S-transferases are dimeric cytosolic enzymes that are organized, based upon
their amino acid homology, into six classes- zeta (ζ), pi (π), alpha(α), omega (Ω), mu (µ), and
theta (Θ). Glutathione is a tri-peptide consisting of glutamate and cysteine through gamma
linkage and glycine through peptide bond (Eaton and Bammler, 1999; Kim, et al., 2013; Ziglari
and Allameh, 2013).
In the case of AFB 1, GSTs catalyze the reaction between the nucleophilic sulfur atom in
the cysteine residue of GSH with the electrophilic substrate, with the resultant AFB-GSH adduct
safely eliminated in the urine and feces (Wang et al., 1999; Ziglari and Allameh, 2013) (Figure
3). Glutathione S-transferase activity is routinely quantified using prototype assays involving
bioactivated substrates such as 1-chloro-2,4-dinitrobenzene (CDNB), 1,2-dichloro-4nitrobenzene (DCNB), ethacrynic acid (ECA), and cumene hydroperoxide (CHP) (Awasthi, 2007;
Habig and Jakoby, 1981; Habig et al., 1974b). Previous studies in our laboratory identified and
cloned six turkey alpha class GSTs, tGSTA 1.1, 1.2, 1.3, 2, 3, and 4 (Kim et al., 2010; Kim et al.,
2011). Cloned and expressed tGSTAs possessed detectable activities toward prototypical
substrates (Kim, et al., 2011). The cloned tGSTA1.2 and A3 had the highest activities toward
CDNB, ECA, and CHP, whereas tGSTA1.1 possessed the highest activity toward DCNB (Kim, et
al., 2011). Even though tGSTA1.1 is missing a signature motif, detectable catalytic activity was
measured for all substrates (Kim, et al., 2011). Cytosolic tGSTAs possessed activities toward all
GST prototype substrates, however these activities were significantly lower than those
observed for mouse cytosol except for ECA (Kim, et al., 2011). All cloned and expressed tGSTAs
possessed measurable AFBO-conjugating activity compared to non-cloned hepatic tGSTAs (Kim,
et al., 2011; Kim, et al., 2013). Domesticated hepatic turkey GSTs lack detoxifying activity, while
16

wild varieties have fully functional GSTs (Kim, et al., 2011; Kim, et al., 2013). These six turkey
GST genes are homologs of AFB1-protective GSTAs in mice and other species (Kim, et al., 2010).
The catalytic activity of hepatic turkey GSTAs toward AFBO are substantially lower or not
detected compared to that of mGSTA3, the “gold standard” for AFBO detoxification (Kim, et al.,
2013). The importance of GSTA3 in other species was confirmed with the demonstration that
GSTA3 knockout mice are substantially more AFB1-susceptible than wild-type mice (Ilic et al.,
2010). Studies in our laboratory have consistently demonstrated that hepatic GSTs from
domesticated turkeys lack AFBO detoxifying activity (Kim, et al., 2013), indicating that the ratelimiting step in species sensitivity toward AFB1 is GST mediated detoxification of the AFBO
metabolite (Eaton and Bammler, 1999; Kim, et al., 2011). Additionally, the phylogeny of poultry
GSTs was constructed to illustrate the relatedness of these GSTAs between chickens, heritage,
wild, and domesticated turkeys (Kim, et al., 2013). This study concluded that turkey and chicken
GSTAs are orthologous, and that the GSTA loci was established before speciation (Kim, et al.,
2013).

Quail
Our laboratory has previously determined the extreme sensitivity of poultry species to
AFB1 that was observed during “Turkey X Disease” is most likely due to a deficiency of
protective hepatic glutathione S-transferases (GSTs) (Kim, et al., 2011; Klein et al., 2000).
Importantly, studies from our laboratory showed that unlike the hepatic forms, recombinant
GSTAs from domesticated turkeys have the ability to conjugate and detoxify AFBO (Kim, et al.,
2013), leading to the conclusion that GST silencing is not due to sequence changes within the
17

GST coding region, but more plausibly due to regulatory gene abnormalities in domestic turkeys
not present in their wild counterparts (Coulombe et al., 2005; Kim, et al., 2011). The use of
purified metabolic proteins has provided many insights and answers to how these enzymes
interact with AFB1.
While turkeys are among the most susceptible species studied, quail, a related
Galliforme, appeared in one in vivo feeding study to be less susceptible AFB 1 when considering
gross hepatic lesions and lethality (Arafa et al., 1981). Another study demonstrated that quail
microsomal preparations produced significantly lower bioactivation metabolites (as measured
by both production of metabolites AFB1-dihydrodiol, AFB-GSH, and AFL) than that from turkey
(Lozano and Diaz, 2007). To our knowledge, there have been no studies focusing specifically on
the functional characteristics of CYP- and GST-mediated bioactivation and detoxification in quail
liver.
Given the centrality of these two opposing metabolizing pathways in AFB1 toxicology in
turkeys, the purpose of this study was to characterize the kinetic and functional properties of
microsomal CYP and cytosolic GST enzymatic activities of Coturnix japonica (JQ) and Callipepla
californica (HQ). These properties were compared against those of domesticated and wild
turkeys with a view to determine whether these reflect differences in in vivo susceptibility
between quail and turkeys.

Research Goals
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The research goals were to characterize microsomal and cytosolic enzyme activities
from Japanese (JQ) and Hawaiian (HQ) quail with regards to AFB1, CDNB, DCNB, CHP, and ECA.
Comparing the results to Broad-breasted white (BB) and Eastern Wild turkeys (EW). Doing so
would allow the assessment of the susceptibility of quail with respect to other poultry species
and it would generate further insight about the mechanisms of AFB 1 bioactivation and
detoxification.

Materials and Methods
Supplies and Reagents
1-chloro-2,4-dinitrobenzene (CDNB), 1,2-Dichloro-4-nitrobenzene (DCNB), ethacrynic acid
(ECA), cumene hydroperoxide (CHP), GSH, glutathione reductase, nicotinamide adenine
dinucleotide (NADPH), AFB1, aflatoxin G 1 (AFG1), butylated hydroxytoluene (BHT),
phenylmethylsulphonyl fluoride (PMSF), sucrose, 85% H3PO4, tetrahydrofuran (THF), and
isopropyl-b-D-thiogalactopyranoside (IPTG) were obtained from Sigma–Aldrich (St Louis, MO).
Bradford Protein Assay Kit was from Bio-Rad (Philadelphia, PA). The PTFE membranes were
purchased from Millex Samplicity Filters (Tullagreen, Carringtonhill, Co Cork IRL). Turkey starter
mash obtained from IFA Country Stores (Salt Lake City, UT). Custom anti-peptide antibodies for
P450 1A5 (Rabbit anti-serum BLD#1, Lot#33964, Rabbit#G5415), P450 3A37 (Rabbit anti-serum
BLD#1, Lot#33965, Rabbit#G5424), GSTA3 (Rabbit anti-serum #1 [A3R2], Lot#35788-35789,
Rabbit#G7496), and GSAT4 (Rabbit anti-serum #2 [A4R2-2], Lot#35790-35791, Rabbit# G7510)
were prepared by Genemed Synthesis Inc. (San Antonio, TX). The anti- β-actin antibody
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(ab8224) was purchased from Abcam (Cambridge, UK). The remaining immunoblot reagents
(streptavidin-HRP, anti-rabbit secondary, and the chemiluminescent substrate) were from
ProteinSimple (San Jose, CA).

Animal Tissues
The liver tissues used were from two varieties of Quail, Callipepla californica (HQ) and
Coturnix japonica (JQ) obtained from the Deschambault Research Station Quebec, Canada. The
livers were flash-frozen in liquid N2, shipped overnight on dry ice, and stored at -80 °C until use.
Turkeys were purchased from Strombergs hatchery (Hackensack, MN) and raised at Utah State
University South Farm. Female poults were identified by PCR and culled (Kalina et al., 2012).
Male poults were fed starter mash and livers harvested at approximately three weeks of age.
Livers were flash frozen in liquid N2, transported on dry ice, and stored at -80 °C. Swiss-Webster
mice were obtained from Charles River Laboratories (Wilmington, MA) through Laboratory
Animal Research Center, Utah State University and were given a diet containing 0.75%
butylated hydroxyanisole (BHA) using corn oil for 14 days. Animals were housed in an AAALACaccredited facility, and all procedures involving animal care and tissue collection were approved
by Utah State University’s Animal Care and Use Committee (approvals #2668 and 2670).

Isolation of Hepatic and Cytosolic Proteins
Microsomes and cytosols were isolated by pooling approximately 2 g of liver tissue from
two birds in each group, resulting in a total of 4 HQ and 3 JQ samples. Proteins were purified
through differential centrifugation as described previously (Klein, et al., 2000). All steps were
20

performed at 4 °C. Frozen livers were homogenized using a Polytron (Brinkman, Westbury, NY)
in a 1:3 w/v cold homogenizing buffer (50 mM Tris, 1 mM EDTA, 0.25 M sucrose, 150 mM KCl,
20 mM BHT, 200 mM PMSF, pH 7.4). Homogenate was centrifuged at 10,000 x g for 10 min then
supernatant was centrifuged at 16,000 x g for 10 min then at 105,000 x g for 60 min.
Supernatants (consisting of liver cytosols) were collected, aliquoted and stored at -80 °C. The
microsomal pellet was homogenized and centrifuged at 105,000 x g (L7-55 ultracentrifuge
Beckman Coulter, Indianapolis, IN), for 60 min and the pellet collected, aliquoted, and stored at
-80 °C until assayed. Proteins were quantified using the Bradford assay (Kim, et al., 2011).

Quantifying AFB1 Bioactivation and Detoxification
Bioactivation of AFB1 to AFBO and detoxification activities of AFBO to exo-AFB1-GSH
(AFB-GSH) were performed according to published methods(Kim, et al., 2011; Rawal and
Coulombe, 2011) . Turkey liver microsomes (~400 µg total protein for control sample) and quail
microsomes (~50 µg total protein) were used as the P450 source for AFB1 bioactivation which
were reacted in 0.1 mM Tris buffer (pH 7.6) containing 10-1024 µM AFB1 in HPLC grade
dimethyl sulfoxide, 2 mM NADPH, 5 mM GSH, and BHA-Induced mouse cytosol (~800 µg total
protein for each sample and ~3 µg total protein for control sample) as the GST source to “trap”
the short-lived AFBO (Guarisco, et al., 2008; Klein, et al., 2000). The mixture was incubated in
epoxide trapping buffer (5 mM MgCl2, 25 mM KCl, 0.25 mM sucrose, and 80 mM K2HPO4, pH
7.6) to give a final volume of 250 μl. The mixture was incubated for 10 min with the cofactor
mix at 37 °C, then incubated an additional 20 min with the AFB1. The reaction was stopped by
adding 250 uL of cold MeOH spiked with 24 µM AFG 1 as an internal standard. The samples were
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left overnight at -20 °C to facilitate precipitation and then centrifuged for 11 min at 17,000 G.
Supernatants were filtered through a 0.2 µM hydrophilic PTFE membrane and 160 µL was
injected into an HPLC. Metabolites were separated on a Shimadzu LC system (Pleasanton, CA),
equipped with a model LC-20AD pump, a model SPD-20AV UV/vis detector, and an Allsphere
ODS-2.5 uM (250 × 4.6 mm) column (Grace Davison Discovery Sciences, Columbia, MD) kept at
40 °C. The elution of the peaks was monitored by UV absorbance (λ = 365 nm). Mobile phases
and elution programs used were as previously reported (Kim, et al., 2011). Metabolite
formation was quantified using a calibration curve generated using authentic exo-AFB1-GSH
standard. Bioactivation of AFB1 from turkey samples was performed as described (Rawal and
Coulombe, 2011).
Quail hepatic cytosolic GST-mediated detoxification of AFBO to AFB-GSH was measured
by a modification of the above protocol. Quail liver cytosol (~100 µg total protein) was
substituted for the BHA-induced mouse cytosol. The AFBO metabolite was enzymatically
generated by using turkey liver microsomes (~400 µg total protein). Detoxification of AFBO
from turkey samples was performed as described (Kim, et al., 2011).

GST Prototype assays
Specific enzyme activities were assayed using previously established protocols for
activity toward prototype substrates ethacrynic acid (ECA), 1,2-dichloro-4-nitrobenzene (DCNB),
and 1-chloro-2,4-dinitrobenzene (CDNB) (Habig and Jakoby, 1981; Habig et al., 1974a), and
cumene hydroperoxide (CHP) (Lawrence and Burk, 1976). The assays were optimized for a final
volume of 200 µL of 100 mM phosphate buffer at room temp (25°C) using a Synergy H1
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microplate reader (Biotek, Winooski, VT), with the exception of ECA which was performed in a 1
mL volume using a Genesys 6 spectrophotometer (Thermo Spectronic, Madison, WI): (1) 0.2
mM ECA, 0.25 mM GSH, ΔA270 nm (Extinction coefficient: 5/mM/cm), and buffer pH 6.5, (2) 1
mM DCNB, 5mM GSH, ΔA345 nm (8.5/mM/cm), and buffer pH7.5, (3) 1 mM CDNB, 1 mM GSH,
ΔA340 nm (9.6/mM/cm), and buffer pH 6.5, and (4) CHP glutathione peroxidase activity was
determined using 1.2 mM CHP, 2mM GSH, 1 U Glutathione reductase, 0.2 mM NADPH, ΔA340
nm (6.22/mM/cm), and buffer pH 7.0.

Expression of CYPs and GSTs
Expression of CYPs and GSTs were quantified by immunoblots using ProteinSimple WesTM
system utilizing the 12-230 kDa 25 capillary separation module, performed according to the
manufacturer’s instructions, except the antibody incubation time was increased from 30 min to
60 min per the manufacturers recommendation. The proteins were diluted to 0.50 mg/mL for
both quail varieties and for EW; while BB was diluted to 2.0 mg/mL for labeling with both
isoforms of P450 (1A5 and 3A37) and GSTA (A3 and A4). The anti-peptide dilution used was
1:50 for both P450 1A5 and 1:10 for P450 3A37 for all samples. Proteins were identified using
the following antipeptide concentrations 1:50 tGSTA3 and 1:50 tGSTA4 for turkey, 1:50 tGSTA3
and 1:250 tGSTA4 for quail. 1:10 (29 kDa) System loading control and 1:100 (90 kDa) System
loading control were used for P450 and GSTA immunoblots, respectively.

Statistical Analysis
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Kinetic data and statistics analyzed Prism by nonlinear regression for Michaelis-Menten
and Kcat equations using (GraphPad Software, San Diego, CA).

Results and Discussion
Although quail are generally regarded to be of intermediate susceptibility among
poultry, with turkeys the highest (Arafa et al., 1981), a direct comparison has been complicated
by a lack of direct in vivo AFB1 feeding trials between these two species of equivalent age,
gender, AFB1 intake, and toxicity endpoints. In the absence of such definitive studies,
quantifying activities and metabolic profiles of specific phase I and phase II enzymes can
accurately predict in vivo comparative toxicity (Kim, et al., 2013; Klein, et al., 2000).
In turkeys and most other animals studied, metabolic bioactivation of AFB1 is catalyzed
by orthologs of turkey CYPs 1A5 and 3A37 (Rawal, et al., 2010b; Yip and Coulombe, 2006).
Hepatic expression of these CYPs was determined from immunoblots using custom anti-peptide
antibodies prepared against the turkey forms of these enzymes previously cloned, expressed
and functionally characterized in our laboratory (Rawal, et al., 2010b; Yip and Coulombe, 2006).
For all liver samples, CYPs 1A5 and 3A37 appeared at the expected molecular weights of 60 and
58kD, respectively (Rawal, et al., 2010b; Yip and Coulombe, 2006). As shown in Figure 4, quail
liver, like that from turkey, constitutively express both of these CYP forms. Hepatic expression
of CYP1A5 was not significantly different between quail, but was significantly greater than that
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from turkey. Conversely, there were no significant differences between and among species with
respect to expression of CYP3A37 (Figure 4).

A

B

Figure 4: Immunoblots showing expression of CYP1A5 (A) and 3A37 (B) from liver microsomes from Japanese (JQ) and
Hawaiian Quail (HQ), and Broad-breasted White (BB) and Eastern Wild (EW) Turkeys. A] CYP1A5 B] CYP3A37. Custom Turkey
anti-P450 peptides and HRP-conjugated anti-Rabbit secondary antibody were used and bands were detected by
chemiluminescence analysis. Each sample represents two pooled liver samples corresponding to three unique pooled microsome
samples. Arrows indicate the protein band of interest and the associated molecular weight.
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Cytochrome P450-mediated bioactivation to AFBO, the metabolite most responsible for
the toxic and carcinogenic effects of this mycotoxin, is accurately quantified as the trapped
AFB-GSH adduct (Klein, et al., 2000) using exogenous GST in the microsomal incubations due to
the transient nature of AFBO (t0.5 ~ 0.5 sec; (Eaton et al., 1994)). Bioactivation from livers
prepared from both quail and turkeys exhibited traditional Michaelis saturation kinetics (Figure
5). At a substrate concentration of 128 µM, CYP-mediated formation of AFBO in microsomes

A

B

Figure 5: Michaelis-Menten (A) and Lineweaver-Burke (B) plots for AFB1 bioactivation by Japanese and Hawaiian Quail (JQ,
HQ) and Domesticated and Wild Turkey (BB, EW) Liver Microsomes. Enzyme kinetics of AFB1 epoxidation activity in liver
microsomal proteins (A and B). Panel A shows SE for each data point, with an N of 3. R2 values were 0.97, 0.84, 0.84, and 0.89
respectively.
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prepared from HQ and JQ were not significantly different from each other, but were
significantly (p < 0.05) lower than those from domesticated and wild turkeys, respectively (HQ:
2.14 ± 1.80; JQ: 1.89 ± 0.69; BB: 69.06 ± 6.28; EW: 104.90 ± 3.72 nmol/min/mg protein). In all
cases, quail microsomes exhibited significantly lower maximum rates (Vmax), lower catalytic
affinity of enzyme for substrate (Km), and lower specificity (Kcat) (Table 1).

Table 1

HQ

Kinetics of Hepatic Microsomal P450 Bioactivation of AFB1 to AFBO for Hawaiian (HQ) and
Japanese Quail (JQ) and, Broad-breasted White (BB) and Eastern Wild (EW) Turkeys.
Vmax
Km
Kcat
(nmol/min/mg protein)
(µM AFB1)
(s-1)
a
a
-04
2.28 ± 0.54
214.92 ± 13.43
8.61X10 ± 1.79X10-04 a

JQ

2.49 ± 0.12 a

231.50 ± 18.96 a

1.08X10-03 ± 5.03X10-05 a

BB

3.87 ± 0.27 b

178.25 ± 2.17 b

1.73X10-03 ± 9.29X10-06 b

EW

4.52 ± 0.28 b

129.10 ± 18.91 c

1.82X10-03 ± 1.09X10-04 b

Data are mean (+ SE; n=3); different superscript letters represent significant difference (P < 0.05). The AFBO column represents the
bioactivation of Aflatoxin B1 (AFB1) to the AFB1-8,9-epoxide (AFBO) intermediate in microsomes, calculated for the 128 µM AFB1 treatment.
1 AFB1-8,9-epoxide (AFBO); GSH (5mM)

In humans and in most animals studied, the principal route of detoxification and single most
important determinant for species resistance regardless of efficiency of AFB1 bioactivation is via
hepatic GSTs (Eaton and Bammler, 1999). As shown in Figure 6, liver cytosolic fractions
prepared from all species expressed both GSTA3 and GSTA4, subunits that putatively catalyze
conjugation of AFBO with GSH (Kim, et al., 2013). Bands were observed for GSTA3 and GSTA4 at
the expected a MW of 29 kDa (Figure 6 A and B) (Kim, et al., 2011). Apparent expression shows
significant difference in expression of GSTA3 between turkey and quail (Figure 6).
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A

B

Figure 6: Immunoblots of Japanese (JQ) and Hawaiian Quail (HQ), and Broad-breasted White (BB) and Eastern Wild (EW)
Turkey Hepatic Protein Expression for GSTA3 (A) and GSTA4 (B). A] GSTA3 B] GSTA4. Custom Turkey anti-GSTA peptides and
HRP-conjugated anti-Rabbit secondary antibody were used and bands were detected by chemiluminescence analysis. Each
sample represents two pooled liver samples corresponding to three unique pooled cytosol samples. Arrows indicate the protein
band of interest and the associated molecular weight. Blots were truncated between ~50-110kd.

The most specific and state-of-the-art method of measuring GST-mediated AFB1
detoxification in liver cytosolic fractions is by an HPLC-based method that employs liver
microsomes to generate AFBO that is then trapped by GSTs in the cytosolic fraction (Eaton, et
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al., 1994). Cytosolic AFBO detoxification in livers prepared from both quail and turkeys
exhibited traditional Michaelis saturation kinetics (Figure 7). At a substrate concentration of
128 µM, hepatic cytosols from quail were significantly more active in AFB-GSH formation than
that in turkeys (HQ: 188.69 ± 0.13; JQ: 504.17 ± 0.24; BB: n.d.; EW: 18.40 ± 0.40 pmol/min/mg
protein). Among quail, conjugation activity in JQ was significantly greater than in HQ (Table 2).

A

B

Figure 7: Michaelis-Menten (A) and Lineweaver-Burke (B) plots showing kinetics of GST-mediated AFBO detoxification by
Japanese and Hawaiian Quail (JQ, HQ) and Domesticated and Eastern Wild Turkey (BB, EW) Liver Cytosols. Enzyme kinetics of
AFB1 detoxification in liver cytosolic proteins (A and B). Saturation curve was determined using AFB1 concentrations of 10 to
1024 μM. Panel A shows SE for each data point with an N of 3. R2 values were 0.92, 0.81, 1.00, 0.79 respectively.
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The AFB-GSH formation, presented as Vmax rates, is significantly different between HQ
and JQ. However, both quail species presented rates slightly lower than that of EW. Cytosolic
AFBO detoxification in livers from HQ and JQ exhibited significantly lower catalytic affinity of
enzyme for the AFBO substrate (Km), and lower specificity (Kcat) than that from EW. (Table 2).
Detoxification of the prototype substrates CDNB, DCNB, ECA and CHP provide further
information on hepatic GST activity, though these activities are not relevant to AFB1 per se but
can be used in larger cross-species comparisons. Unlike BB and EW, neither HQ nor JQ
possessed the ability to metabolize DCNB, while quail had significantly lower metabolic activity
toward CDNB than turkeys (Table 3). Cytosols from both quail species had lower metabolic
activities toward ECA and CHP compared to those from BB and EW.

Table 2

HQ

Kinetics of Hepatic Cytosolic GST mediated Detoxification of AFBO to AFB-GSH in Hawaiian (HQ) and
Japanese Quail (JQ) and, Broad-breasted White (BB) and Eastern Wild (EW) Turkeys.
Vmax
Km
Kcat
(nmol/min/mg protein)
(µM AFB1)
(s-1)
0.12 ± 0.02 a
169.82 ± 32.71 a
1.75X10-05 ± 8.76X10-06 a

JQ

0.15 ± 0.01 b

184.34 ± 25.09 b

3.25X10-05 ± 2.03X10-06 b

BB

n.d.

n.d.

n.d.

EW

0.18 ± 0.01 c

27.03 ± 9.69 c

4.21X10-05 ± 4.21X10-06 c

Data are mean (+ SE; n=3); different superscript letters represent significant difference (P < 0.05). The AFB-GSH column represents the formation of the
trapped epoxide in cytosol, calculated for the 128 µM AFB1 treatment.
Abbreviations: n.d. is not detected.
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Table 3 Cytosolic Detoxification of GST Pseudosubstrates in Hepatic Cytosols from Hawaiian (HQ) and
Japanese Quail (JQ) and, Broad-breasted White (BB) and Eastern Wild (EW) Turkeys.
Specific enzyme activity (nmol/min/mg protein)
1
CDNB
DCNB2
ECA3
CHP4
HQ
19.10 ± 1.67 a
n.d.
25.38 ± 0.10 a
141.33 ± 4.94 a
JQ

25.64 ± 1.77 a

n.d.

27.45 ± 1.44 a

172.86 ± 8.37 a

BB

380.40 ± 40.07 b

0.80 ± 0.08 a

78.12 ± 2.67 b

56.70 ± 1.14 b

EW

306.40 ± 24.99 b

0.76 ± 0.10 a

47.65 ± 7.43 c

46.40 ± 1.98 b

Data are mean (+ SE; n=3); different superscript letters represent significant difference (P < 0.05). The AFBO column represents the bioactivation of
Aflatoxin B1 (AFB1) to the AFB1-8,9-epoxide (AFBO) intermediate in microsomes. The AFB-GSH column represents the formation of the trapped epoxide
in cytosol.
11-Chloro-2,4-dinitrobenzene (CDNB): GSH (1mM);
21,2-Dichloro-4-nitrobenzene (DCNB): GSH (5mM);
3Ethacrynic acid (ECA); GSH (2.5mM);
4 Cumene Hydroperoxide (CHP); GSH (2mM);
Abbreviations: n.d. is not detected.

Quail are like other avian species regarding metabolism of exogenous substrates by liver
enzymes. This study examined two genera of quail, Gallipepla californica (HQ) and Coturnix
japonica (JQ), to rank quail susceptibility to AFB 1 toxicity as a species against turkey of which we
have known susceptible (BB) and resistant (EW) varieties (Kim, et al., 2011). Species
susceptibility to AFB1 has been described as a balance between P450-mediated AFBO
production, and the efficiency with which this reactive intermediate is detoxified through GST
conjugation (Eaton and Gallagher, 1994). Mice efficiently bioactivate AFB 1 to produce AFBO
through high-affinity P450s and are substantially resistant to AFB1 owing to the expression of
the A3 GST subunit (mGSTA3), which has a high catalytic activity toward AFBO (Kim, et al.,
2011). The current knowledge indicates that the efficiency of GST conjugation is a principal
“rate-limiting” determinant for AFB1 action in individuals and species (Ilic, et al., 2010).
Investigations from our laboratory have previously demonstrated the extreme sensitivity of
turkeys to the effects of AFB1, due to the presence of high affinity and high epoxidation activity
of P450s toward AFB1 (Rawal, et al., 2010a; Rawal et al., 2009; Rawal, et al., 2010b; Yip and
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Coulombe, 2006). The toxic effects of the bioactivated AFBO metabolite in quail was studied by
the Oliveira group who observed typical aflatoxicosis symptoms such as, hepatic cell
vacuolation with fatty infiltration in all treatment groups (Oliveira et al., 2002). Additionally, bile
duct proliferation and trabecular disorder in treatment groups that received 0.1 ppm AFB1
(Oliveira, et al., 2002). These studies provided important information on the acute and chronic
effects of AFB 1 for quail production, giving insight to the relevant toxic doses and confirming
that quail suffer from the same toxic effect as other poultry species.
Only a few research groups have done metabolic analysis of quail enzymatic
bioactivation and detoxification toward AFB1 and AFBO. As was observed in turkey hepatic
microsomes (Rawal, et al., 2010b), cytosols (Kim, et al., 2011), and expressed tGSTAs, quail
microsomal and cytosolic proteins possess catalytic activity for both bioactivating AFB 1 to AFBO
and detoxifying AFBO to AFB-GSH. There have not been any studies, to date, that address the
relative susceptibility of quail versus other Galliformes to AFB1 insult. Those previous studies
focused more on the transportation and movement of AFB1 and related metabolites within a
given species of bird. These studies cannot accurately be analyzed and compared to the current
study. The current study utilized the same techniques previously performed on turkey species
to determine relative resistance and susceptibility toward AFB 1. Compared to previous studies
utilizing the same techniques and end points it is clear that quail microsomes are not as
efficient at bioactivating AFB1 to AFBO (Rawal, et al., 2010b). However, quail cytosols possess
similar catalytic detoxifying activity toward AFBO compared to turkeys (Kim, et al., 2011).
As previously observed in turkey hepatic cytosols (Kim, et al., 2011), quail cytosols
possessed catalytic activity toward the GST substrates CDNB, ECA, and CHP, however, DCNB
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activity was not detected. Similar observations have been previously made (Dai et al., 1996),
however, the GSTs isolated were fractioned and tested individually, as opposed to using whole
cytosolic proteins. The Dai group observed similar trends in the conjugating activity of quail
GSTs toward prototype substrates. Notably, DCNB is not a suitable substrate for quail Alpha
class GSTs as either no or only marginal activity was measured, a conclusion that is similar to
current study. However, the specific activity of the enzymes is different, most likely an effect of
the difference in and the purity of the protein preparations. Therefore, direct comparisons
cannot be made between the two studies as the protein preparations are quite different;
however, activity was detected for CDNB, CHP, and ECA in both studies. The GST enzyme
activities for the prototypical substrates were determined using established protocols (Habig
and Jakoby, 1981; Lawrence and Burk, 1976).
The molecular weights (MW) of P450 CYP1A5 and CYP3A37 along with GSTA3 and
GSTA4 were consistent with the expected molecular weights of analogous proteins in turkey.
The MW of quail P450s and GSTs observed in this study correlate with the MW observed
previously for CYP1A5 (Diaz, et al., 2010a) and CYP3A37 (Dai, et al., 1996). Where the Diaz
group only observed quail P450 enzymes analogous to the hCYP2A6 and hCYP3A4 families the
current study observed the presence of P450 enzymes analogous to tCYP1A5 and tCYP3A37,
homologs of human CYP1A2 and 3A4, using turkey antipeptide serum to label the proteins
(Diaz, et al., 2010a). The Dai group (Dai, et al., 1996) observed molecular weights between 26 –
27 kDa as opposed to the 29 kDa observed in this study for the GSTA enzymes. This observation
confirms that quail hepatic proteins possess P450 and GSTA enzymes homologous to human
and turkey enzymes (Dai, et al., 1996).
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The current study characterized the kinetics of quail P450s and GSTs to understand the
susceptibility of quail to the toxic effects of AFB1 in comparison to other Galliformes. The data
indicates there is as much variation between quail genera as there is between poultry species,
which suggests that quail susceptibility to AFB 1 varies between genera. Quail P450s bioactivate
AFB1 to AFBO at a significantly slower rate (Vmax), a greater substrate concentration (Km), and at
a slower turnover rate (Kcat) than those of turkeys. Concluding that quail P450s are less efficient
at bioactivating AFB1 to AFBO. The detoxifying activity of quail GSTs toward AFBO is significantly
different from both mouse and turkey cytosolic proteins. The EW turkey species possessed
greater detoxifying ability, while the two genera of quail are statistically different from one
another with JQ having greater detoxifying activity than that of HQ. The expression of each
metabolizing enzyme isoform and the correlated kinetic rates indicate the observed difference
in susceptibility. Quail livers expressed more CYP1A5 than turkey livers did, however, turkey
liver CYP1A5 proteins have an overall lower Km of bioactivation. Leading to the conclusion that
the order of susceptibility based on bioactivation is not different than what has previously been
published, ducklings >>> turkey (EW > BB) > quail (JQ > HQ) > mouse. Conversely, quail livers
expressed more GSTA3 enzyme with a significantly greater cytosolic protein detoxifying Km
compared to the BB turkey species, with JQ being more efficient than HQ. Interestingly the
detoxifying ability of EW turkey species is more efficient than both of the quail species and the
BB turkey species. In terms of detoxification the data concludes that the order of susceptibility
is ducklings >>> turkey (BB) > quail (HQ > JQ)> turkey (EW) > mouse. Additional studies are
needed to further clarify our understanding of quail phase I and II metabolic enzymes in
relation to other Galliformes. Specifically, additional studies isolating and identifying the
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specific contributions of the identified individual P450s and GSTA enzymes involved in the
metabolism of AFB1 with a greater number of individual animals and variety of poultry species.
The study should prioritize characterizing the above poultry species utilizing the AFB-GSH
detoxified metabolite as the endpoint. The AFB-GSH detoxified metabolite is the best metric to
determine susceptibility of poultry species to the toxic effects of AFB1. As such, a study in which
duck, chicken, turkey, quail, pheasant, mice, and rats are all characterized at the same time will
provide the most comprehensive data on the matter.
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